StreetAlpha.app
Home › Stocks › CGON

CG Oncology, Inc. (CGON)

Healthcare
$79.47
▼ −2.97%
LAST CLOSE · NOV 20

CG Oncology develops cretostimogene, an investigational bladder cancer immunotherapy given directly into the bladder. It last closed at $79.47 on Nov 20, down 2.97% on the day. The next earnings report for CGON is expected around Fri, Feb 26, 2027. For the quarter ended Sep 2026, CGON reported EPS of -$0.64 on revenue of $1.6M, with revenue down 3.7% from a year ago. Over its last 8 reports the stock moved an average of 5.3% the session after earnings. Over the last 12 months CGON insiders bought $27.5M of stock on the open market and sold $4.9M, according to SEC Form 4 filings.

AI Auto Pilots
Is CGON in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold CGON.

Key Stats

Last 12 months
Results
Revenue
$6.2M
+183.6% vs a year ago
Net income
−$237.5M
−3851.1% margin
EPS (diluted)
−$2.76
Free cash flow
−$189.2M
−3068.0% margin
Valuation
Market cap
$7.1B
89.3M shares
P/E
–
No P/E while losing money
Price to sales
1151.2
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$28.2M
At Sep 30
Debt
$3.0M
At Sep 30
Shareholder equity
$991.0M
Shares outstanding
89.3M
At Nov 4
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2023: $204K$204KFY2023FY2024: $1.1M$1.1MFY2024FY2025: $4.0M$4.0MFY2025

From CGON's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 6). Last 12 months adds up the four latest quarters.

Next report
Feb 26
Estimated date · Time not announced
Reported EPS
-$0.64
Quarter ended Sep 2026
Year ago EPS
-$0.57
Same quarter last year
Revenue
$1.6M
−3.7% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.48Dec '24Mar 2025: -$0.45Mar '25Jun 2025: -$0.54Jun '25Sep 2025: -$0.57Sep '25Dec 2025: -$0.51Dec '25Mar 2026: -$0.71Mar '26Jun 2026: -$0.90Jun '26Sep 2026: -$0.64Sep '26Latest -$0.64
Revenue by quarter
Dec 2024: $456,000Dec '24Mar 2025: $52,000Mar '25Jun 2025: $0Jun '25Sep 2025: $1.7MSep '25Dec 2025: $2.3MDec '25Mar 2026: $1.1MMar '26Jun 2026: $1.2MJun '26Sep 2026: $1.6MSep '26Latest $1.6M
How CGON moved after its last 8 reports
Average move the session after a report ±5.3%
Nov 6, 2026Time not announced+17.3%
Aug 6, 2026Time not announced+3.4%
May 8, 2026Time not announced+0.6%
Feb 27, 2026Time not announced+4.8%
Nov 14, 2025Time not announced+8.6%
Aug 8, 2025Time not announced+2.0%
May 13, 2025Time not announced−3.9%
Mar 28, 2025Time not announced−1.9%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on CGONStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
Analyst calls from around the web
Last 90 days on CGON: 0 upgrades, 0 downgrades, 0 initiations
Truist FinancialReiterated
Nov 17Buy 

StreetAlpha's curated list of analyst calls collected from around the web. It may be incomplete or inaccurate, is not a consensus and is not advice.

AI Starter and AI Pro
Full analyst coverage on CGON
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on CGON

Technical Analysis

CGON · as of the Nov 20 close · updated each morning
Uptrend

The stock is 11% above its 20 day and 13% above its 50 day average. It is 15% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 60). The nearest support is the Pivot S1 at $78.07, and the nearest resistance the swing high (Nov 6) at $80.03.

Short trendBullish
Long trendBullish
MomentumStrong
StretchNormal
VolatilityHigh, 7.0%/day
Key levels
$93.9552 week high+18.2%
$82.02Pivot R1+3.2%
$80.61Pivot+1.4%
$80.03Swing high (Nov 6)+0.7%
$79.47Last close
$78.07Pivot S1−1.8%
$73.50Swing low (Aug 14)−7.5%
$71.28100 day average−10.3%
$71.0420 day average−10.6%
$68.8550 day average−13.4%
$67.40200 day average−15.2%
$37.0152 week low−53.4%
Indicators
RSI (14)60.46Strong, overbought above 70Neutral
MACD3.95Above its signal lineBullish
Stochastic58.6Middle of its rangeNeutral
ADX (14)30.3Trending up
Williams %R-45.8Oversold below −80, overbought above −20Neutral
CCI (20)98.2Oversold below −100, overbought above 100Neutral
Rate of change+4.6%Change over 10 sessionsBullish
ATR (14)$5.60Typical daily range, 7.0% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for CGON

What happened before

See how CGON did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Whale Options Flow

90D
Whale options flow for CGONHow many large options trades hit CGON, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

CGON Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲126 buying vs 103 selling
  • ●Held by funds -0.1 pts
  • ▲Funds holding +5
  • ▲Superinvestors: 2 added, 0 cut
  • ▲Put/call 0.42 to 0.14
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding234229+2.2%
In funds' top 101110+10.0%
Held by funds105.0%105.0%−0.1 pts
New / increased39 / 8731 / 92+2.4%
Reduced / sold out69 / 3471 / 38−5.5%
Put/call ratio0.140.42−67.0%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See CGON institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

CGON Insider Trading

All filings →
Insider trading · 12 months
Insiders are net buyers
Bought$27.5M3 buys · 3 insiders
Sold$4.9M13 sales · 2 insiders
100% of the selling was under pre-arranged trading plans.
Cluster buy: 2 insiders bought $2.7M between Nov 18 and Nov 18.
2026-01 sold $585K2026-03 sold $125K2026-04 sold $1.1M2026-06 bought $24.8M2026-06 sold $848K2026-07 sold $1.9M2026-08 sold $75K2026-09 sold $73K2026-10 sold $62K2026-11 bought $2.7M2026-11 sold $92KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 18Isabel KalofonosChief Commercial OfficerBuy3,751$79.75$299K
Nov 18Arthur KuanCEOBuy30,000$78.88$2.4M
Nov 16Leonard E PostDirectorSale plan1,000$92.00$92K
Oct 15Leonard E PostDirectorSale plan1,000$62.06$62K
Sep 15Leonard E PostDirectorSale plan1,000$72.98$73K
Aug 14Leonard E PostDirectorSale plan1,000$74.54$75K
Every insider buy and sale for CGON over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See CGON insider trades →

From SEC Form 4 filings by CGON's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CGON is in one of them and how their past CGON trades turned out.

CGON in the AI portfolios
Loading…

CGON News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered CGON in an article yet. Here's the latest on the wider market.

CGON in the news

About CG Oncology

CG Oncology is a clinical stage biopharmaceutical company developing cretostimogene, an investigational immunotherapy for bladder cancer. The treatment is delivered directly into the bladder and is being studied in patients with high risk and intermediate risk forms of the disease that have not grown into the muscle wall of the bladder. The company is based in Dallas, Texas, and its intended customers are patients with bladder cancer and the urology practices that treat them.

Headquarters
Dallas, TX